These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9743463)

  • 1. Vitravene--another piece in the mosaic.
    Crooke ST
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):vii-viii. PubMed ID: 9743463
    [No Abstract]   [Full Text] [Related]  

  • 2. New CMV retinitis drug approved.
    Body Posit; 1998 Oct; 11(10):10. PubMed ID: 11365907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fomivirsen approved for CMV retinitis.
    Roehr B
    J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fomiversen sodium approved to treat CMV retinitis.
    Piascik P
    J Am Pharm Assoc (Wash); 1999; 39(1):84-5. PubMed ID: 9990192
    [No Abstract]   [Full Text] [Related]  

  • 5. Fomivirsen approved.
    AIDS Patient Care STDS; 1998 Dec; 12(12):943. PubMed ID: 11362071
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
    Highleyman L
    BETA; 1998 Oct; ():5. PubMed ID: 11365993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in CMV management: fomivirsen (Vitravene) approved.
    Proj Inf Perspect; 1998 Dec; (26):7. PubMed ID: 11366499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fomivirsen approved for CMV retinitis: first antisense drug.
    AIDS Treat News; 1998 Sep; (302):7. PubMed ID: 11365764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First "antisense" drug will treat CMV retinitis.
    Marwick C
    JAMA; 1998 Sep; 280(10):871. PubMed ID: 9739955
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA grants marketing clearance of Vistide for the treatment of CMV retinitis.
    AIDS Patient Care STDS; 1996 Dec; 10(6):383-4. PubMed ID: 11361576
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA notifications. FDA approves generic foscarnet sodium injection.
    AIDS Alert; 2005 Jul; 20(7):82. PubMed ID: 16110563
    [No Abstract]   [Full Text] [Related]  

  • 12. New CMV drug won't replace other therapies.
    AIDS Alert; 1998 Nov; 13(11):124-6. PubMed ID: 11365968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fomivirsen for the treatment of cytomegalovirus retinitis.
    Jabs DA; Griffiths PD
    Am J Ophthalmol; 2002 Apr; 133(4):552-6. PubMed ID: 11931791
    [No Abstract]   [Full Text] [Related]  

  • 14. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense drugs progressing through product pipelines.
    Traynor K
    Am J Health Syst Pharm; 2002 Nov; 59(21):2046-7. PubMed ID: 12434715
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration.
    J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):30. PubMed ID: 11363758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cidofovir recommended for approval for CMV retinitis.
    James JS
    AIDS Treat News; 1996 Apr; (no 244):6-7. PubMed ID: 11363308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First eye implant approved.
    AIDS Alert; 1996 May; 11(5):59. PubMed ID: 11363254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration.
    Baker R
    BETA; 1995 Dec; ():8. PubMed ID: 11363015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological abnormalities following intravitreal vitravene (ISIS 2922) in two patients with CMV retinitis.
    Zambarakji HJ; Mitchell SM; Lightman S; Holder GE
    Br J Ophthalmol; 2001 Sep; 85(9):1142. PubMed ID: 11561556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.